All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Completed, but no date, and reported results Terminated | 2007-004866-42 | An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX alone for Second-line Treatment of Patients with Metastatic Clororectal Cancer... | bad-data | |
Reported results Terminated | 2008-000803-26 | A controlled randomized double-blind multi-center phase II study of FOLFOX6 or FOLFIRI combined with sorafenib versus placebo in second-line metastatic colorectal carcinoma | 2012-10-02 | due-trials |
Completed, but no date, and reported results | 2008-007798-18 | An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination with Epirubicin, Cisplatin and Capecitabine (ECX) versus ECX Chemotherapy alone in Subjects with Locally Advanced Gastr... | bad-data | |
Reported results | 2008-007974-39 | Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyrimi... | 2015-08-14 | due-trials |
Completed, but no date, and reported results Terminated | 2009-014725-16 | Double-blind, placebo-controlled, randomized phase II-study investigating the efficacy of Bevacizumab for symptom control in patients with malignant ascites due to advanced-stage gastrointestinal canc... | bad-data | |
Reported results | 2009-017731-17 | An open-label 2:1 randomized phase II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first-line treatment of patients with non-resectable metastatic colorectal cancer and RAS wild-type | 2022-01-20 | due-trials |
Reported results | 2010-020606-15 | An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer | 2015-05-27 | due-trials |
Reported results | 2010-022938-85 | Comparison of two preemptive treatment strategies of panitumumab mediated skin toxicity and assessment of quality of life in patients with Ras-wildtype colorectal cancer | 2016-03-01 | due-trials |
Completed, but no date, and reported results | 2010-024111-13 | Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy | bad-data | |
Reported results | 2011-001024-38 | Randomisierte Phase II Studie zum Vergleich der Therapie Vinorelbin in Kombination mit dem mTOR-Inhibitor Everolimus vs. Vinorelbin Monotherapie in der Zweitlinienbehandlung von Patientinnen mit metas... | 2016-10-31 | due-trials |
Completed, but no date, and reported results | 2011-001507-13 | Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin (FLOT) in combination with Trastuzumab in patients with HER2-positive, locally advanced resectable... | bad-data | |
Completed, but no date, and reported results | 2012-004550-28 | EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3... | bad-data | |
Not reported | 2012-005422-30 | Randomized Phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumumab ... | 2023-02-17 | due-trials |
Listed as ongoing, but also has a completion date | 2013-002742-37 | Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer | 2020-10-16 | bad-data |
Reported results | 2013-004796-12 | Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Prospektive, randomisierte Phase-II Studie zur intensivie... | 2020-02-19 | due-trials |
Completed, but no date, and reported results Terminated | 2013-005545-37 | A Phase II Study of Cabazitaxel for Patients with Breast or Lung Cancer and Recurrent or Progressive Brain Metastases (CaBaMet) Phase II Studie zur Behandlung mit Cabazitaxel von Patienten mit rezi... | bad-data | |
Reported results | 2013-005559-34 | Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer - The AIO-NEONAX trial (AIO-PAK-0313) A prospective, randomized, controlled, phase II study ... | 2022-10-21 | due-trials |
Completed, but no date, and reported results Terminated | 2014-001983-36 | Maintaining ERBB blockade in EGFR-mutated lung cancer (MARBLE) - A randomized, open-label, phase II study of maintaining pan-ERBB blockade following platinum-based induction chemotherapy in patients w... | bad-data | |
Completed, but no date | 2014-004086-24 | Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel/Ge... | bad-data | |
Reported results Terminated | 2014-005595-28 | Induction therapy with gefitinib followed by taxane platinum chemotherapy and intercalated gefitinib in NSCLC stages II-IIIB with activating EGFR mutation – A single arm Phase II trial. Einleitung... | 2017-03-16 | due-trials |
Reported results | 2015-001123-22 | A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous - Non-Small Cell Lung C... | 2020-11-24 | due-trials |
Other | 2015-001478-16 | Rivaroxaban in the treatment of venous thrombembolism (VTE) in cancer patients – a randomized phase III Study Randomisierte Phase III Studie zum Stellenwert von Rivaroxaban zur Behandlung venöser T... | not-yet-due | |
Reported results | 2015-002773-38 | mFOLFOX6 vs. mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial Kombinationschemotherapie mFOLFOX6 vs. Kombinationschemotherapie mFOLFOX6 +... | 2022-06-01 | due-trials |
Reported results | 2015-005741-31 | Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLC Förderung der Wirksamkeit einer anti-PD-1-Behandlung (Immuntherapie Nivolumab) in Kombination mit Stra... | 2021-05-14 | due-trials |
Not reported | 2016-000399-28 | A phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of pembrolizumab + axitinib ... | 2024-01-16 | due-trials |
Reported results Terminated | 2016-001331-12 | A randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with head and neck cancers | 2021-12-03 | due-trials |
Reported results | 2016-002170-13 | A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months ... | 2020-10-23 | due-trials |
Reported results | 2016-002307-26 | A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma | 2021-10-01 | due-trials |
Completed, but no date | 2016-002467-34 | Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial | bad-data | |
Not reported | 2016-003709-33 | A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies | 2022-03-08 | due-trials |
Not reported | 2016-003963-20 | Durvalumab (MEDI4736) in frail and elder patients with metastatic NSCLC | 2023-01-31 | due-trials |
Completed, but no date | 2016-004434-26 | Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer – The phase II AVETUX-CRC trial. Avelumab und Cetuximab in Kombination mit FOLFO... | bad-data | |
Reported results | 2016-004750-15 | A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma. Eine randomisierte Phase-II-Studie mit Dur... | 2022-08-12 | due-trials |
Reported results | 2016-004857-33 | A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma Eine einarmige klinische Prüfung (Phase ... | 2023-02-17 | due-trials |
Completed, but no date | 2016-005147-17 | Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy Zweitlinientherapie mit Nal-IRI/5-FU/FA nach... | bad-data | |
Reported results | 2017-000105-20 | Neoadjuvant anti PD-1 immunotherapy in resectable non-small cell lung cancer Neoadjuvante anti-PD-1 Immuntherapie bei operablem nichtkleinzelligen Lungenkrebs | 2023-05-05 | due-trials |
Not reported | 2017-000624-10 | Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma - The randomized phase 2 INTEGA ... | 2022-03-05 | due-trials |
Not reported | 2017-001538-25 | A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbladd... | 2022-03-15 | due-trials |
Reported results | 2017-002056-86 | A multicenter open-label phase II trial to evaluate Nivolumab and Ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer Eine multizentrische offene Phase... | 2021-11-20 | due-trials |
Reported results | 2017-003349-14 | A randomized phase II study on the optimization of immunotherapy in squamous carcinoma of the head and neck (OPTIM) Eine randomisierte Phase-II-Studie zur Optimierung der Immuntherapie bei Plattene... | 2021-06-20 | due-trials |
Not reported | 2017-003553-42 | A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) Eine offene, einarmig... | 2021-12-10 | due-trials |
Reported results | 2017-003780-35 | Randomized phase II, open-label efficacy and safety study of second-line durvalumab plus tremelimumab versus platinum-based chemotherapy alone in patients with NSCLC and first-line checkpoint-inhibito... | 2022-08-31 | due-trials |
Completed, report not yet due | 2019-001707-21 | Single-Arm Phase II-Study in Patients with extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide Eine einarmige Phase-II-Studie ... | 2024-04-12 | not-yet-due |
Reported results | 2020-002605-25 | Neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer (NEOBIL) Neoadjuvante Therapie mit Bintrafusp alfa bei Patienten mit operablem Krebs der Gallenwege (NEOBIL) | 2022-01-05 | due-trials |
Other | 2020-002715-21 | Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMR-deficient stage II high risk or stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy– a Phase II study (ANTONI... | not-yet-due | |
Other | 2020-003512-27 | Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study | not-yet-due | |
Reported results Terminated | 2020-005771-12 | Neoadjuvant encorafenib, binimetinib and cetuximab for patients with BRAF V600E mutated/pMMR localized colorectal cancer | 2024-02-09 | due-trials |